Kanamicina Atb

Kanamycin, the active ingredient in Kanamicina Atb, is a aminoglycoside antibiotic presented as a sterile ophthalmic solution for ocular use. It is employed to treat bacterial infections of the eye, particularly when the causative organisms are known to be susceptible to kanamycin.

GNH USA supplies Kanamicina Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanamicina Atb (kanamycin) is used to treat bacterial eye infections caused by susceptible organisms.

- Bacterial conjunctivitis: reduces bacterial load and promotes rapid resolution of infection. - Bacterial keratitis: inhibits bacterial proliferation in the cornea, aiding healing. - Corneal ulcer caused by susceptible bacteria: provides bactericidal activity to prevent progression and facilitate tissue repair.

Kanamicina Atb may cause local and systemic adverse reactions when administered to the eye.

Common Side Effects: - Ocular irritation or burning sensation. - Redness of the conjunctiva. - Excessive tearing or discharge. - Blurred vision temporarily. - Foreign‑body sensation. - Mild allergic conjunctivitis.

Serious or Rare Side Effects: - Corneal epithelial toxicity or ulceration. - Severe allergic reaction including anaphylaxis. - Systemic ototoxicity with prolonged use. - Nephrotoxicity in patients with systemic absorption. - Vision loss due to severe corneal damage.

Use of Kanamicina Atb requires careful consideration of patient‑specific factors.

- Renal impairment: monitor renal function as systemic absorption may be increased. - Pregnancy: avoid unless clearly indicated, as safety data are limited. - Known hypersensitivity: do not use in patients allergic to aminoglycosides. - Contact lens wearers: discontinue lens use during treatment and monitor for irritation. - Concomitant ototoxic drugs: avoid co‑administration with agents that may increase ear toxicity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Kanamicina Atb can interact with other medications that affect renal function or ototoxicity risk.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., vancomycin, loop diuretics): increase risk of kidney injury. - Ototoxic drugs (e.g., furosemide): may potentiate hearing loss. - Neuromuscular blocking agents: can enhance neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase corneal toxicity when used together. - Systemic antibiotics: concurrent use may alter bacterial flora and affect efficacy.